EGFR and pancreatic neoplasm: In this study, we report the development of 89Zr (t1/2 = 3.27 d) labeled MEHD7945A (89Zr-MEHD7945A) and an evaluation of its pharmacological properties in PDAC by evaluating in vivo spatial distribution of the tracer against regional localization of EGFR and HER3 in Kras wild-type (BxPC-3) and mutant (AsPC-1) pancreatic cancer.